Skip to main content
. Author manuscript; available in PMC: 2013 Dec 26.
Published in final edited form as: JAMA. 2013 Jun 26;309(24):10.1001/jama.2013.6882. doi: 10.1001/jama.2013.6882

Figure 1.

Figure 1

Treatment of Prostate Cancer Among Men Who Are the Least Likely to Benefit

The percentage of treatment was adjusted for age, race, socioeconomic class, comorbidity, tumor grade, year of diagnosis, and Surveillance, Epidemiology, and End Results region. Use of advanced treatment technologies significantly increased among prostate cancer patients with low-risk disease, high risk of noncancer mortality, and both low-risk disease and high risk of noncancer mortality (P<.001 for trend). Conversely, there was a decreased use of prior standards among these patients (P<.001 for trend), making the overall use of treatment relatively stable over time. Error bars indicate 95% CIs; EBRT, traditional external beam radiation treatment; IMRT, intensity-modulated radiotherapy.